VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Interest Expense : $0.00 Mil (TTM As of Jun. 2008)

View and export this data going back to . Start your Free Trial

What is VioQuest Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. VioQuest Pharmaceuticals's interest expense for the three months ended in Jun. 2008 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2008 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. VioQuest Pharmaceuticals's Operating Income for the three months ended in Jun. 2008 was $ -1.03 Mil. VioQuest Pharmaceuticals's Interest Expense for the three months ended in Jun. 2008 was $ 0.00 Mil. VioQuest Pharmaceuticals has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

VioQuest Pharmaceuticals Interest Expense Historical Data

The historical data trend for VioQuest Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VioQuest Pharmaceuticals Interest Expense Chart

VioQuest Pharmaceuticals Annual Data

Trend

Dec98

Dec99

Dec00

Dec01

Dec02

Dec03

Dec04

Dec05

Dec06

Dec07

Interest Expense

Get a 7-Day Free Trial

VioQuest Pharmaceuticals Quarterly Data
	Sep03	Dec03	Mar04	Jun04	Sep04	Dec04	Mar05	Jun05	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

VioQuest Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

VioQuest Pharmaceuticals (OTCPK:VOQP) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

VioQuest Pharmaceuticals's Interest Expense for the three months ended in Jun. 2008 was $0.00 Mil. Its Operating Income for the three months ended in Jun. 2008 was $-1.03 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2008 was $0.00 Mil.

VioQuest Pharmaceuticals's Interest Coverage for the quarter that ended in Jun. 2008 is calculated as

VioQuest Pharmaceuticals had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VioQuest Pharmaceuticals Inc (OTCPK:VOQP) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 2287, Minneapolis, MN, USA, 55402

Website

VioQuest Pharmaceuticals Inc is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment.

Executives

Mark D Dacko	director, officer: CFO and Secretary	800 NICOLLET MALL SUITE 2690, MINNEAPOLIS MN 55402
Christopher P. Schnittker	officer: V.P. & Chief Financial Officer	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Brian Lenz	officer: CFO and Treasurer	65 COMMERCE WAY, HACKENSACK NJ 07601
Lau Johnson Yiu Nam	director
Michael Weiser	director	C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Stephen Rocamboli	director, officer: Secretary	C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Daniel E Greenleaf	director, officer: President and CEO	C/O NABI BIO PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487
Lester E Lipschutz	10 percent owner	WOLF BLOCK SCHORR AND SOLIS COHEN, 1650 ARCH STREET, PHILADELPHIA PA 19103
David M Tanen	director	TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Headlines

No Headlines